Company Overview
Snapshot
Founded in June 2016 by Ishay Attar, BioChange operates with 11–50 employees. The company has secured $3.05 million across three funding rounds from two investors.
Business overview
BioChange specializes in tissue regeneration technology, developing CellFoam, an injectable scaffold designed to stimulate tissue repair and remodeling. This minimally invasive solution, based on natural biomaterials, mimics the extra-cellular matrix to encourage the body's natural healing processes. The company operates within the Health Tech & Life Sciences sector, focusing on biomaterials and tissue engineering, and serves markets including healthcare providers and pet owners with products like Revolette, CellFoam, VetFoam, and ReGum.
Strategic signal
In September 2022, BioChange's CellFoam technology, designed to reverse receding gums, showed success in dog trials and was anticipated for human use. This development signals significant progress in regenerative medicine, indicating the company's potential to address unmet needs in dental health and beyond, validating its innovative approach to tissue regeneration for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is BioChange's core technology?
- BioChange's core technology is CellFoam, an injectable scaffold made from natural biomaterials that stimulates tissue repair and remodeling by mimicking the extra-cellular matrix.
- When was BioChange founded and by whom?
- BioChange was founded in June 2016 by Ishay Attar.
- What was a key development for BioChange in September 2022?
- In September 2022, BioChange's foam technology for reversing receding gums showed success in dog trials and was slated for human use.
- What is the primary sector BioChange operates in?
- BioChange operates primarily in the Health Tech & Life Sciences sector, with a focus on biomaterials and tissue engineering.